How Analysts Feel About SCYNEXIS, Inc. (NASDAQ:SCYX)?

Investors sentiment decreased to 0.59 in 2018 Q4. Its down 0.83, from 1.42 in 2018Q3. It dropped, as 10 investors sold SCYNEXIS, Inc. shares while 7 reduced holdings. 7 funds opened positions while 3 raised stakes. 16.73 million shares or 13.88% less from 19.42 million shares in 2018Q3 were reported.
Geode Management Ltd holds 0% or 470,130 shares in its portfolio. Royal Comml Bank Of Canada stated it has 4,720 shares. Rbf Ltd Llc holds 11,100 shares. Northern Corporation accumulated 112,293 shares or 0% of the stock. 191,041 were accumulated by Blackrock Inc. 19,455 are owned by National Bank Of Ny Mellon. Moreover, Caxton Corp has 2.53% invested in SCYNEXIS, Inc. (NASDAQ:SCYX) for 4.33 million shares. Creative Planning invested in 50,176 shares. Sabby Ltd Com reported 15,764 shares. National Asset Management Inc holds 227,341 shares. Dimensional Fund Advsrs L P accumulated 0% or 197,241 shares. Private Advisor Grp Limited Com owns 200,000 shares. Vanguard Grp has invested 0% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX). Deutsche Savings Bank Ag holds 0% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX) for 252,600 shares. Moore Lp has invested 0% in SCYNEXIS, Inc. (NASDAQ:SCYX).

Since April 17, 2019, it had 1 buying transaction, and 0 insider sales for $40,750 activity.

SCYNEXIS, Inc. (NASDAQ:SCYX) Ratings Coverage

Among 3 analysts covering SCYNEXIS (NASDAQ:SCYX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SCYNEXIS had 6 analyst reports since March 15, 2019 according to SRatingsIntel. On Monday, March 18 the stock rating was maintained by Maxim Group with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 19. The rating was maintained by Needham on Friday, March 15 with “Buy”. Below is a list of SCYNEXIS, Inc. (NASDAQ:SCYX) latest ratings and price target changes.

03/05/2019 Broker: BidaskScore Rating: Sell Downgrade
15/04/2019 Broker: BidaskScore Rating: Hold Upgrade
24/03/2019 Broker: BidaskScore Rating: Hold Upgrade
19/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $4.5 Maintain
18/03/2019 Broker: Maxim Group Rating: Buy New Target: $4 Maintain
15/03/2019 Broker: Needham Rating: Buy New Target: $5 Maintain

The stock increased 1.95% or $0.03 during the last trading session, reaching $1.57. About 271,107 shares traded. SCYNEXIS, Inc. (NASDAQ:SCYX) has declined 24.10% since May 8, 2018 and is downtrending. It has underperformed by 28.47% the S&P500.

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. The company has market cap of $83.35 million. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. It currently has negative earnings. The firm also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis.

More notable recent SCYNEXIS, Inc. (NASDAQ:SCYX) news were published by: which released: “SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens – PRNewswire” on April 08, 2019, also with their article: “SCYNEXIS up 26% after hours on positive ibrexafungerp data – Seeking Alpha” published on January 30, 2019, published: “SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) – PRNewswire” on May 01, 2019. More interesting news about SCYNEXIS, Inc. (NASDAQ:SCYX) were released by: and their article: “Health Care Sector Update for 01/31/2019: ABC,SCYX,PULM – Nasdaq” published on January 31, 2019 as well as‘s news article titled: “SCYNEXIS Inc. – MarketWatch” with publication date: February 06, 2017.

SCYNEXIS, Inc. (NASDAQ:SCYX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.